Silence Therapeutics

SLN

London, United Kingdom· Est. 1994

Silence Therapeutics is a clinical-stage RNA interference (RNAi) company focused on developing novel siRNA therapeutics. As a pioneer in the field, the company's core technology, mRNAi GOLD™, enables the targeted delivery of siRNAs to hepatocytes in the liver. Its lead asset, zerlasiran (SLN360), is in Phase 2 development for cardiovascular risk reduction, and the company has established significant collaborations with AstraZeneca and Hansoh Pharma to expand its pipeline and validate its platform.

silence-therapeutics.com

SLN · Stock Price

USD 5.20+1.88 (+56.63%)

Market Cap: $257.0M

Historical price data

AI Company Overview

CardiovascularHematologyMetabolicRare Diseases

Technology Platform

Proprietary mRNAi GOLD™ platform for the design and delivery of GalNAc-conjugated short interfering RNAs (siRNAs) to hepatocytes in the liver for targeted gene silencing.

Pipeline

7 drugs in pipeline

Drug	Indication	Stage
SLN360 + Placebo	Cardiovascular Diseases	Phase 2
SLN124 + Placebo	Polycythemia Vera	Phase 1/2
Atu027 & gemcitabine in lead in safety period + Atu027 & gem...	Carcinoma, Pancreatic Ductal	Phase 1/2
Atu027	Advanced Solid Tumors	Phase 1
SLN124 + Placebo	Non-transfusion-dependent Thalassemia	Phase 1

Funding History

Total raised:$40M

PIPE$40MUndisclosedJul 15, 2020

IPOUndisclosedUndisclosedJun 15, 2005

Opportunities

The primary growth opportunity lies in the vast, untapped market for Lp(a) lowering, where zerlasiran could be a first-in-class therapy.

Further platform partnerships and expansion into new hepatic disease targets represent additional avenues for value creation and non-dilutive funding.

Risk Factors

Key risks include clinical trial failures, particularly for lead asset zerlasiran; intense competition from larger, established RNAi companies; and reliance on partners for a significant portion of pipeline progress and funding.

Competitive Landscape

Main competitors are Alnylam Pharmaceuticals (market leader) and Arrowhead Pharmaceuticals in the RNAi space. Silence differentiates through its proprietary mRNAi GOLD™ chemistry platform and focused strategy on specific genetic targets like Lp(a) and TMPRSS6, supported by validation from major pharma collaborations.